These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26439803)

  • 1. Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer.
    Park S; Langley E; Sun JM; Lockton S; Ahn JS; Jain A; Park K; Singh S; Kim P; Ahn MJ
    Oncotarget; 2015 Oct; 6(31):30929-38. PubMed ID: 26439803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
    Becker DJ; Wisnivesky JP; Grossbard ML; Chachoua A; Camidge DR; Levy BP
    Clin Lung Cancer; 2017 Jan; 18(1):e35-e40. PubMed ID: 28029530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
    Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
    J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.
    Nishie K; Kawaguchi T; Tamiya A; Mimori T; Takeuchi N; Matsuda Y; Omachi N; Asami K; Okishio K; Atagi S; Okuma T; Kubo A; Maruyama Y; Kudoh S; Takada M
    J Thorac Oncol; 2012 Nov; 7(11):1722-7. PubMed ID: 23059777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
    Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
    Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
    Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
    PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.